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Background: HIV-1 Vpr-mediated G2 cell cycle arrest is dependent on the interaction of Vpr with an E3 ubiquitin
ligase that contains damage-specific DNA binding protein 1 (DDB1), Cullin 4A (Cul4A), DDB1 and Cul4-associated
factor 1 (DCAF1), and Rbx1. Vpr is thought to associate directly with DCAF1 in the E3 ubiquitin ligase complex
although the exact interaction pattern of the proteins in the complex is not completely defined. The Vpr of SIVagm
induces G2 arrest of cognate African Green Monkey (AGM) cells but not human cells. The molecular mechanism by
which SIVagm Vpr exhibits its species-specific function remained unknown.
Methods: Physical interaction of proteins in the E3 ubiquitin ligase complex was assessed by co-immunoprecipitation
followed by western blotting. In addition, co-localization of the proteins in cells was investigated by confocal
microscopy. The cell cycle was analyzed by propidium iodide staining and flow cytometry. DNA damage response
elicited by Vpr was evaluated by detecting phosphorylation of H2AX, a marker for DNA damage response.
Results: We show that RNAi knock-down of DCAF1 prevented the co-immunoprecipitation of DDB1 with HIV-1
Vpr while DDB1 knock-down did not influence the binding of Vpr to DCAF1. HIV-1 Vpr mutants with a L64P or a
R90K mutation maintained the ability to associate with DCAF1 but did not appear to be in a complex with DDB1.
SIVagm Vpr associated with AGM DCAF1 and DDB1 while, in human cells, it binds to human DCAF1 but hardly
binds to human DDB1, resulting in the reduced activation of H2AX.
Conclusions: The identification of Vpr mutants which associate with DCAF1 but only poorly with DDB1 suggests
that DCAF1 is necessary but the simple binding of Vpr to DCAF1 is not sufficient for the Vpr association with
DDB1-containing E3 ligase complex. Vpr may interact both with DCAF1 and DDB1 in the E3 ligase complex.
Alternatively, the interaction of Vpr and DCAF1 may induce a conformational change in DCAF1 or Vpr that
promotes the interaction with DDB1. The ability of SIVagm Vpr to associate with DDB1, but not DCAF1, can
explain the species-specificity of SIVagm Vpr-mediated G2 arrest.
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The Vpr accessory protein is encoded by all lentiviruses
but its role in virus replication and pathogenesis is not
well understood. Vpr is related by amino acid sequence
to the Vpx accessory protein which is encoded by SIVmac
and HIV-2. Both Vpr and Vpx are packaged into virions
through an interaction with p6 region of HIV Gag [1,2],* Correspondence: hakata@med.kindai.ac.jp
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cation. Vpr is not required for virus replication in acti-
vated CD4+ T cells but enhances the ability of the virus
to infect macrophages [3,4]. Vpr-deleted SIVmac repli-
cates in Rhesus macaques but tends to revert back to
the wild-type, suggesting an important role of this
accessory protein in pathogenesis [5,6]. While several
functions have been proposed for Vpr such as nuclear
import of the preintegration complex, transactivation of
viral genes, dysregulation of cellular gene expression,
and impairment of mitochondrial functions [7-19], theLtd. This is an Open Access article distributed under the terms of the Creative
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iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Hakata et al. Virology Journal 2014, 11:108 Page 2 of 11
http://www.virologyj.com/content/11/1/108most widely accepted feature of Vpr function is its
ability to induce G2 cell cycle arrest [20,21].
Vpr induces G2 cell cycle arrest through its association
with the E3 ubiquitin ligase CRL4-DCAF1, a complex that
consists of the damage-specific DNA binding protein 1
(DDB1), Cullin 4A (Cul4A), the DDB1 and Cul4-associated
factor 1 (DCAF1) and Rbx1 [22-28]. DCAF1 is identical to
Vpr binding protein (VprBP) that was previously iden-
tified [29,30]. The amino- and carboxy-terminal regions of
Cul4A are responsible for its interaction with DDB1 and
Rbx1, respectively. The adaptor DDB1 links Cul4A to a
variety of substrate specificity subunits, DCAFs. Many
DCAFs identified so far contain specific WDXR motifs
[31-34] and the WDXR motif in DCAF1 has been re-
ported to be necessary for the association both with
DDB1 and Vpr [25]. The region of Vpr required for bin-
ding to DCAF1 was mapped to the leucine-rich motif
within the third alpha-helix domain of Vpr [30]. A Vpr
mutant, VprQ65R, which is mutated at 65th amino acid
residue in this motif, lost the binding to DCAF1 and the
ability to arrest cell cycle at G2 phase [25]. In previous re-
ports, the association of Vpr with DCAF1 and DDB1 was
examined by co-immunoprecipitation using several Vpr
mutants and the results indicated that the binding to
DCAF1 fully coincided with the association with DDB1
for all tested mutants [22-24,27]. From these results, Vpr
association with DDB1 is thought to be indirectly me-
diated by simple binding of Vpr to DCAF1.
SIVmac Vpx also contains the carboxy-terminal alpha
helix that is conserved in Vpr. Mutation of the conserved
glutamine Q76 residue in this motif, which is correspon-
ding to the Q65 residue of Vpr, disrupts the binding of
Vpx to DCAF1, suggesting that Vpx uses the conserved
helix domain for interaction with DCAF1 in a manner
similar to Vpr [25,35]. By interacting with the CRL4-
DCAF1 E3 ligase complex, Vpx targets sterile alpha motif
domain- and HD domain-containing protein 1 (SAMHD1)
for proteasomal degradation to counteract the SAMHD1-
mediated lentivirus restriction [36,37]. A recent report
resolved the crystal structure of protein complex com-
prising SIVsm Vpx, the WD40 domain of DCAF1, and the
carboxy-terminal region of SAMHD1 [38].
Molecular mechanism by which Vpr induces G2 arrest
remains unresolved. In particular, a cellular target(s) of the
Vpr-CRL4-DCAF1 E3 ligase have not been identified. It
has been reported that Vpr activates the DNA damage
sensing protein, ataxia telangiectasia mutated and Rad3-
related protein (ATR), resulting in the phosphorylation of
several proteins including Chk1 and histone 2A variant
X (H2AX) [39-43]. A significant portion of Vpr appears
to colocalize with the phopshorylated-form of H2AX
(γH2AX) in the nucleus [39,44]. The current model
for the Vpr-meidated G2 arrest is that Vpr binds to the
CRL4-DCAF1 complex through DCAF1 to recruit a yetunknown target on the E3 ligase and the recruited target
is subsequently ubiquitinated and degraded, resulting in
activation of ATR followed by G2 cell cycle arrest [22-28].
It was recently reported that untimely activation of
the SLX4 complex is involved in the Vpr-mediated G2
arrest [45].
SIVagm also encodes the vpr gene and SIVagm Vpr in-
duces G2 cell cycle arrest in cognate African green mon-
key (AGM) cells but not in human cells while the Vpr of
SIVmac induces G2 cell cycle arrest of monkey cells as
well as human cells [46,47]. The molecular basis of the
species-specificity is still unanswered. In addition to the
G2 cell cycle arrest, SIVagm Vpr targets SAMHD1 in
AGM cells for proteasomal degradation [48].
While it is clear that Vpr or Vpx forms a complex with
DCAF1 in the CRL4-DCAF1 E3 ubiquitin ligase, the
interaction among these proteins in the ligase complex are
not completely defined. Here we show that point mutants
of HIV-1 Vpr that maintain their ability to interact with
DCAF1 do not associate with the CRL4 E3 ubiquitin
ligase, suggesting that simple binding of Vpr to DCAF1 is
distinguishable from the association with DDB1 in the E3
ligase. SIVagm Vpr expressed in human cells readily asso-
ciated with human DCAF1 but only poorly with human
DDB1 while it interacted both with AGM DCAF1 and
AGM DDB1 in AGM cells. The species-specific dys-
function of SIVagm Vpr in inducing G2 arrest in human
cells may therefore be caused by its failure to properly as-
sociate with DDB1 in the CRL4 E3 ubiquitin ligase.
Results
Vpr interaction with the CRL4-DCAF1 complex is
dependent upon DCAF1
Vpr is thought to associate with the CRL4-DCAF1 E3 ubi-
quitin ligase by binding directly to DCAF1 [22-28] as
shown in Figure 1A where Vpr binding to DCAF1 is ne-
cessary and sufficient for the association. To evaluate this
model, we knocked-down DCAF1 or DDB1 and tested
whether this affected the ability of Vpr to associate with
the CRL4-DCAF1 complex. For this, we transfected HeLa
cells with siRNA against DCAF1 or DDB1. A day later,
the cells were transfected with pcHA-Vpr, which is an ex-
pression vector for HIV-1 Vpr tagged with HA (HA-Vpr).
After another two days culture, Vpr was immunoprecipi-
tated with anti-HA MAb and coimmunoprecipitated
DCAF1 and DDB1 were detected on an immunoblot.
The results showed that the DCAF1 and DDB1 siRNAs
knocked-down their respective targets about 80% as com-
pared to a control siRNA which had no effect (Figure 1B).
Knock-down of DCAF1 decreased the amount of DDB1
that associated with Vpr. In contrast, knock-down of
DDB1 did not affect the amount of DCAF1 associated
with Vpr. We also noticed that knock-down of DDB1
























































































































Figure 1 DCAF1 is required for the association of Vpr with
DDB1. (A) A model of the Vpr-CRL4-DCAF1 E3 ubiquitin ligase complex
in which Vpr directly contacts DCAF1. (B) HeLa cells were transfected
with siRNAs targeting DCAF1 or DDB1. A control siRNA is included
and two siRNAs were used against DCAF1. A day later, the cells were
transfected again with HA-Vpr expression vector. After another two days,
HA-Vpr complexes were immunoprecipitated with anti-HA antibody.
Co-immunoprecipitated DCAF1 and DDB1 were detected on an
immunoblot. A nonspecific band is indicated with an asterisk.
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another DDB1 siRNA that targeted a different site on the
mRNA (data not shown). The dependence of Vpr on
DCAF1 for its association with DDB1 and the lack of
dependence of Vpr on DDB1 for the association with
DCAF1 suggest that Vpr interacts directly with DCAF1
which mediates the association with DDB1. These results
are consistent with the recent model (Figure 1A) showing
that DCAF1 is necessary for the association of Vpr with
DDB1 in the CRL4 E3 ligase complex.
HIV-1 Vpr point mutants that bind DCAF1 but poorly bind
to DDB1
If Vpr binding to DCAF1 which is bound to DDB1 is
critical for the Vpr-induced G2 cell cycle arrest, Vpr mu-
tants that are defective in G2 arrest might fail to bind to
DCAF1 and not associate with the E3 ubiquitin ligasecomplex. Vpr mutants that fall into this category include
Q65R and H71R [24,27]. To further test whether mu-
tants that are functionally deficient in arresting cell cycle
also fail to bind DCAF1, we evaluated additional mutant
Vpr proteins, VprL64P and VprR90K, that have been re-
ported to be defective in inducing G2 arrest [26,49]. In
addition, we also used a VprR90D mutant in which the
charge at amino acid R90 was changed. We transfected
293 T cells with Flag-DCAF1 and HA-Vpr or HA-Vpr
mutant expression vectors and tested the possible asso-
ciation of expressed proteins by coimmunoprecipitation.
In our experiments we found that the addition of exo-
genous DCAF1 helped to increase the steady-state levels
of the transfected Vprs. We believe that this is because
DCAF1 binding is required to stablize the proteins in
the cell and that the cell does not contain sufficient
endogenous DCAF1 to bind the exogenously experssed
Vpr proteins. VprL64P was expressed well and co-
immunoprecipitated DCAF1 to a similar extent as
wild-type Vpr did (Figure 2A). Unexpectedly, VprL64P
co-immunoprecipitated only a small amount of DDB1.
VprQ65R is defective for DCAF1 binding [25] and was
therefore used as a control. Using this mutant, we con-
firmed that VprQ65R did not bind to DCAF1 and DDB1
(Additional file 1: Figure S1), confirming the western
blot results are reliable. VprR90K and VprR90D were
stably expressed and coimmunoprecipitated DCAF1
although VprR90K coimmunoprecipitated less DDB1
compared to wild-type Vpr, a phenotype similar to that
of VprL64P (Figure 2B). VprR90D, a nonconservative
mutant, retained the ability to coimmunoprecipitate
DDB1. To evaluate the ability of VprR90D to arrest the
cell cycle at G2 phase, we analyzed the cell cycle profile
of the transfected cells. Exogenous expression of DCAF1
led to similar expression levels of Vpr and Vpr mutants
(Additional file 2: Figure S2B). We found that VprR90D
induced G2 cell cycle arrest while VprR90K did not
(Additional file 2: Figure S2A). These activities are con-
sistent with the association of Vpr mutants with DDB1.
Vpr induces the degradation of uracil N glycosylase
(UNG2) [26,50]. UNG2 is a natural substrate for the
CRL4-DCAF1 ligase. Although the targeting of UNG2 is
not the cause of Vpr-mediated G2 cell cycle arrest [49],
Vpr is thought to recruit UNG2 to the E3 ligase for deg-
radation [50-52]. To determine whether the mutated Vpr
proteins induced UNG2 degradation, we cotransfected
293 T cells with HA-UNG2 and the mutated Vpr expres-
sion vectors, and evaluated the steady-state level of UNG2
by immunoblot analysis (Figure 2C and D). VprR90K did
not induce UNG2 degradation while VprR90D maintained
this function, supporting the idea that VprR90K does not
associate well with the CRL4-DCAF1 ligase and is not
functional. These findings are not easily compatible with
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Figure 2 Vpr-DCAF interaction is not sufficient for Vpr association with DDB1. (A) 293 T cells were cotransfected with HA-Vpr or HA-VprL64P
and Flag-DCAF1 expression vectors. Vpr was immunoprecipitated with anti-HA antibody and the immunoprecipitates were subjected to immunoblot
analysis with anti-Flag MAb, anti-DDB1 antibody, and anti-HA antibody. (B) HA-Vpr, HA-VprR90K, or HA-VprR90D were expressed with Flag-DCAF1 and
were immunoprecipitated with anti-HA antibody. Coimmunoprecipitated DDB1 and Flag-DCAF1 were detected on the immunoblot. (C) 293 T cells
were transfected with increasing amounts (0.05 μg, 0.1 μg, and 0.2 μg) of HA-Vpr, HA-VprR90K, or HA-VprR90D expression vector together with a
constant amount of HA-UNG2 and Flag-DCAF1 expression vectors. Two days later, the cells were lysed and Vpr and UNG2 were detected by
immunoblot analysis with anti-HA antibody. The βtubulin was detected as a loading control. (D) UNG2 band intensities obtained in (C) were
quantified and normalized to the UNG2 signal of the third lane from the left in (C). The results are representative data of three independent
experiments.
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of Vpr with DDB1. These results also suggest that Vpr
may interact with both DCAF1 and DDB1 in the CRL4-
DCAF1 E3 ubiquitin ligase to mediate its function and the
two binding sites can be genetically dissociated.
The species specificity of SIVagm Vpr is caused by
inefficient association with DDB1 in human cells
SIVagm Vpr has been found to induce G2 arrest in African
green monkey (AGM) but not in human cells [46,47]. To
confirm the species-specificity of SIVagm Vpr, human
293 T and AGM-derived COS cells were transfected with
SIVagm Vpr or SIVmac Vpr expression vector and the cell
cycle profile was analyzed by flow cytometry. In 293 T
cells, SIVmac Vpr induced G2 arrest but SIVagm Vpr did
not (Figure 3A). On the other hand, both SIVmac and
SIVagm Vpr induced G2 arrest in COS cells (Figure 3B).
These findings confirmed the species-specificity of SIVagm
Vpr. To determine whether the specificity is due to
species-specific interaction with DCAF1 and DDB1, we
tested whether SIVagm Vpr form a complex with DCAF1and DDB1 in AGM but not human cells. For this, we trans-
fected 293 T and COS cells with SIVmac or SIVagm Myc-Vpr
expression vector with (for 293 T cells) or without (for
COS cells) Flag-DCAF1 expression vector. We then im-
munoprecipitated Myc-Vpr and determined the amount of
associated DCAF1 and DDB1 by immunoblot analysis. In
human cells, SIVmac Vpr coimmunoprecipitated DCAF1
and DDB1 while SIVagm Vpr coimmunoprecipitated
DCAF1 but only inefficiently coimmunoprecipitated DDB1
(Figure 3C), a phenotype that was similar to VprL64P. In
AGM cells, SIVagm and SIVmac Vpr coimmunoprecipitated
DCAF1 and DDB1 (Figure 3D). SIVmac Vpr was expressed
at lower levels than SIVagm Vpr but the amount of im-
munoprecipitated DCAF1 in the samples was similar,
suggesting that SIVmac Vpr may bind to DCAF1 more effi-
ciently than SIVagm Vpr. The decreased expression of
Myc-tagged SIVmac Vpr was likely not due to protein in-
stability since it pulled-down DDB1 as efficiently as did
the highly expressed SIVagm Vpr in COS cells. Thus, in
human cells, SIVagm Vpr fails to interact efficiently with
complexes that contain DDB1 and does not induce G2
A
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Figure 3 The species-specificity of SIVagm Vpr is correlated with an inability to associate with DDB1 in human cells. (A) 293 T cells were
transfected with SIVmac Vpr or SIVagm Vpr, Flag-DCAF1, and EGFP expression vectors. After two days, the cells were fixed, stained with propidium iodide
and analyzed by flow cytometry. The G2:G1 ratio was calculated after gating for the GFP
+ cells. The results are representative of three independent
experiments. (B) COS cells were transfected and the cell cycle profiles were analyzed as in (A). (C) 293 T cells were cotransfected with myc-Vpr of
SIVmac or SIVagm and Flag-DCAF1 expression vectors. Myc-Vpr was immunoprecipitated with anti-myc MAb and the immunoprecipitated complexes
were analyzed on an immunoblot probed with anti-Flag MAb, anti-DDB1 antibody, and anti-myc MAb. (D) COS cells were transfected with myc-Vpr
of SIVmac or SIVagm. Myc-Vpr was immunoprecipitated with anti-myc MAb and coimmunoprecipitated endogenous AGM DCAF1 and DDB1 were
detected with anti-DCAF1 and anti-DDB1 antibodies.
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with DCAF1 and DDB1, and induce G2 arrest. These re-
sults suggest that the species-specificity of SIVagm Vpr-
induced G2 arrest is caused by the specificity with which
SIVagm Vpr associates with the CRL4 E3 ubiquitin ligase
but not due to its specificity with DCAF1.
SIVagm Vpr does not associate efficiently with DDB1 and
induces less of a DNA damage response
We next compared the affinity of VprR90K and SIVagm
Vpr to DDB1 in human cells. We cotransfected 293 T cells
with the respective HA-Vpr expression vector along with
Flag-DCAF1 expression vector. Vpr proteins were immu-
noprecipitated by anti-HA MAb and DCAF1 and DDB1
in the immunoprecipitates were evaluated (Figure 4A). All
Vpr proteins including wild type HIV-1 Vpr coimmuno-
precipitated DCAF1 at similar efficiency while VprR90K
and SIVagm Vpr coimmunoprecipitated less DDB1 as com-
pared to wild type HIV-1 Vpr. Furthermore, the result alsoshowed that the association of DDB1 with SIVagm Vpr is
less efficient than that with VprR90K which lost the ability
to target UNG2 for proteasomal degradation (Figure 2C).
To further test whether SIVagm Vpr has the reduced
association with the CRL4-DCAF1 complex, we co-
transfected HeLa cells with HIV-1 or SIVagm HA-Vpr
expression vector and assessed the colocalization of Vpr
protein with DDB1 by confocal microscopy. Vpr binds
to chromatin and forms nuclear foci [39,44]. To visualize
Vpr foci, we permeabilized the transfected cells with
Triton X100-containing buffer and fixed them. As ex-
pected, DDB1, HIV-1 Vpr, and SIVagm Vpr foci were
present in the nucleus (Figure 4B). A fraction of the Vpr
foci colocalized with DDB1 dot-like signals. We quan-
tified the extent of co-localization by determining the
percentage of Vpr foci that were also positive for DDB1
(Figure 4C). The results showed that HIV-1 Vpr colo-
calized with DDB1 in a higher number of foci than did
SIVagm Vpr.
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Figure 4 In human cells, SIVagm Vpr does associates less efficiently with the CRL4 E3 ubiquitin ligase. (A) 293 T cells were cotransfected
with HA-Vpr, HA-VprR90K, or SIVagm HA-Vpr and Flag-DCAF1 expression vectors. Vpr was immunoprecipitated with anti-HA antibody and the
immunoprecipitates were analyzed on an immunoblot probed with anti-Flag MAb, anti-DDB1 antibody, and anti-HA antibody. (B) HeLa cells were
transfected with HA-Vpr or SIVagm HA-Vpr expression vector. The transfected cells were permeabilized, fixed, and then incubated with anti-DDB1
and anti-HA antibodies followed by Alexa Fluor 594-anti-rabbit IgG and Alexa Fluor 488-anti-rat IgG. Representative images from an HA-Vpr or
SIVagm HA-Vpr expressing sample are shown. Arrows indicate Vpr foci and DDB1 dots which colocalize. (C) The percentage of Vpr foci colocalized
with DDB1 among total Vpr foci was calculated. More than 170 Vpr foci were evaluated for each sample and three independent experiments
were done. The data are the mean values with standard deviations. P values were calculated by the Student’s t-test with P < 0.05 considered
significant.
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DDB1. As expected, VprR90K colocalized with DDB1
less frequently compared than wild-type Vpr (Additional
file 3: Figure S3), confirming its inefficient association
with DDB1. The amount of Vpr colocalized with DDB1
was higher than that in Figure 4C, perhaps as a result of
stabilization of the protein by DCAF1. Because we de-
tected less association of SIVagm Vpr with DDB1, we
tested whether SIVagm Vpr enhances UNG2 degradation.
As for VprR90K, SIVagm Vpr failed to induce the degrad-
ation of UNG2 (Additional file 4: Figure S4), a finding
that is consistent with the idea that SIVagm Vpr does not
associate efficiently with DDB1.
Vpr induces a DNA damage response in the cell,
which can be detected by phosphorylation of H2AX[42]. The response is initiated through the association of
Vpr with the CRL4-DCAF1 ligase. The phosphorylated
form of H2AX, γH2AX, forms nuclear γH2AX foci [53].
If SIVagm Vpr associates inefficiently with CRL4, then it
should induce fewer γH2AX foci. To test this, we trans-
fected HeLa cells with HIV-1 or SIVagm HA-Vpr expres-
sion vector and then counted the number of γH2AX
foci in the Vpr-expressing cells (Figure 5A and B). The
results showed that SIVagm Vpr induced fewer γH2AX
foci than did HIV-1 Vpr. These results were confirmed
by immunoblot analysis which showed that Vpr led to
an increase in the cellular concentration of γH2AX
and that the increase was less pronounced in SIVagm
Vpr-expressing cells than HIV-1 Vpr-expressing cells







































Figure 5 SIVagm Vpr induces less DNA damage than HIV-1 Vpr. (A) HeLa cells were transfected with HA-Vpr or SIVagm HA-Vpr expression
vector. After two days, the cells were fixed, permeabilized and incubated with anti-γH2AX and anti-HA antibodies. Subsequently, the cells were
stained with Alexa Fluor 594-anti-rabbit IgG and Alexa Fluor 488-anti-rat IgG. (B) The number of γH2AX dots in Vpr expressing cells was counted.
More than 40 Vpr + cells were evaluated in each experiment. Control sample was transfected with pcDNA3.1 instead of Vpr expression vector.
The data represent means with standard deviations from three independent experiments. P values were calculated by Student’s t-test with
P < 0.05 considered as significant.
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human DDB1 in the CRL4-DCAF1 complex and induces
a weaker DNA damage response, resulting in the
species-specific deficiency in G2 cell cycle arrest.
Discussion
Our results suggest that the interaction of Vpr with
DCAF1 is necessary but not sufficient for Vpr function
with respect to G2 cell cycle arrest and UNG2 degra-
dation. The configuration of the Vpr-CRL4-DCAF1 E3
ubiquitin ligase complex is more complicated than pre-
viously thought since our findings showed that some
Vpr point mutants are able to bind DCAF1 but appear
not to interact well with the CRL4-DCAF1 complex. In
addition, SIVagm Vpr, which has species-specificity in
inducing G2 arrest, similarly binds to human DCAF1
but does not associate well with the CRL4-DCAF1 com-
plex in human cells.
In support of the previously predicted direct inter-
action of Vpr with DCAF1, knock-down of DDB1 had
no effect on the association of Vpr with DCAF1. Con-
versely, Vpr did not co-immunoprecipitate DDB1 when
DCAF1 was knocked-down with its siRNAs, supporting
the idea that DCAF1 is required for the association of
Vpr with DDB1. To our knowledge, none of Vpr point
mutants that have previously been analyzed were found
to associate with DCAF1 but not with DDB1 [22-24,27].In this study, we found that VprL64P and VprR90K
maintained the ability to interact with DCAF1 but only
weakly interacted with DDB1. A possible explanation for
our findings was that the Vpr point mutants might have
failed to localize to the nucleus, as this would have
allowed for an interaction with DCAF1 but not with
CRL4 which is in the nucleus. However, we found that
the mutated Vpr proteins actually localized to the nu-
cleus and their localization was not significantly affected
by the overexpression of DCAF1 (data not shown), al-
though overexpression of DCAF1 has been reported to
relocalize Vpr to the cytoplasm [54]. Furthermore, the
cellular distribution pattern of the Vpr mutants was
similar to that of wild-type Vpr in all experimental con-
ditions of this study. Also, the localization of DCAF1 or
DDB1 to the nucleus was not affected by wild-type or
mutated Vpr (data not shown). Therefore, it is unlikely
that the cellular localization pattern of these proteins
causes the reduced binding of Vpr mutants to DDB1.
Both Vpr point mutants, VprL64P and VprR90K, were
defective in inducing G2 cell cycle arrest, suggesting that
Vpr must associate both with DCAF1 and DDB1 to
function. Similar to HIV Vpr point mutants, SIVagm Vpr
did not induce G2 arrest and had inefficient association
with DDB1 despite binding to DCAF1 in human cells.
These results further suggest that the binding of Vpr to
DCAF1 is not sufficient for the interaction of Vpr with
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logical function of Vpr.
Our findings suggest that the association of Vpr with
DDB1 is accomplished by an additional step(s) beyond
the simple binding of Vpr to DCAF1. It is clear that Vpr
interacts with DCAF1 but it is possible that it addi-
tionally interacts with DDB1, thereby strengthening the
complex. The affinity of Vpr for DDB1 alone is not suffi-
cient to be detected in the absence of DCAF1 but may
still contribute to the stability of the complex. It is
possible that L64 and R90 residues of Vpr are directly
involved in formation of the binding interface for this
interaction. Alternatively, the interaction with DCAF1
may induce a conformational alteration in Vpr that
allows binding to DDB1. Paramyxovirus simian virus 5
and hepatitis B virus encode proteins that bind to DDB1
in CRL4 through an alpha-helical motif [55,56]. Vpr is
composed of three alpha-helix domains with flexible ele-
ments at both ends that could similarly bind DDB1. L64
and R90 residues may act as a binding interface after the
conformational change or may be required for the
proper conformational change itself. In this model,
DCAF1 binding to Vpr is a prerequisite for the asso-
ciation with DDB1. Another hypothesis is that binding
of Vpr to DCAF1 may change the DCAF1 conformation
to allow tighter binding to DDB1. Crystallographic ana-
lyses may help to better define these interactions.
UNG2 is degraded by CRL4-DCAF1 E3 ubiquitin ligase
in the absence of Vpr [52] and Vpr enhances this process.
VprR90K was defective for UNG2 degradation most likely
because it failed to associate with DDB1. Alternatively,
VprR90K could inhibit Vpr-independent UNG2 degra-
dation by sequestering DCAF1 from DDB1-containing
CRL4 complexes. In either case, inefficient association
with DDB1 could contribute to the failure to degrade
UNG2. The inability of VprR90K to degrade UNG2 is in-
consistent with a previous report [52] in which VprR90K
caused dose-dependent degradation of UNG2. The reason
for this difference is not clear, but could be caused by the
addition of the exogenous DCAF1 to stabilze the Vpr pro-
teins in our studies.
We have shown that SIVagm Vpr associates weakly
with DDB1 in human cells and the inefficient binding
correlates with its inability to induce G2 arrest. SIVagm
replicates well in some types of human cell [57], as Vpr
is not necessary for virus replication in T cells. However,
the inefficient interaction of SIVagm Vpr with DDB1
could affect virus replication in cell-types such as macro-
phages where Vpr is thought to play a role.
SIVmac and SIVagm Vpr are only about 30% homolo-
gous to HIV-1 Vpr yet interact with the CRL4-DCAF1
complex, highlighting the importance of the E3 ubiquitin
ligase for Vpr function. The interaction was species-
specific in that SIVagm associated with DCAF1 andDDB1 in AGM cells but only with DCAF1 in human
cells. Consistent with this, SIVagm Vpr induced G2 arrest
in AGM cells but not in human cells. It remains unclear
why SIVagm Vpr fails to associate with DDB1 in human
cells. Differences in amino acid sequence of AGM and
human DDB1 may cause the species-specific interaction.
Alternatively, the interaction of SIVagm Vpr with DDB1
may require unidentified cofactors which are differen-
tially expressed in AGM and human cells.
Finally, our findings suggest that analyses of Vpr mu-
tants should determine whether they interact both with
DDB1 and DCAF1, as both interactions play a role in
function. The related lentivirus accessory protein, Vpx,
also associates with the CRL4-DCAF1 ligase and the
interaction is required to induce the degradation of
the host restriction factor SAMHD1. It will be of interest
to determine whether analogous mutations can be
identified in Vpx such that DCAF1 binding is retained
but interaction with the E3 ubiquitin ligase complex is
affected.
Conclusions
HIV-1 Vpr interacts with DCAF1 and DDB1 to induce
G2 arrest, a property that is conserved in SIV Vpr. Iden-
tification of Vpr point mutants that bind to DCAF1 but
only weakly to DDB1 suggests that binding of Vpr to
DCAF1 is not sufficient for the formation of Vpr-CRL4-
DCAF1 E3 ligase complex and the formation is more
complicated processes than previously thought. The
species-specificity of SIVagm Vpr in inducing G2 arrest is
caused by its failure to associate with DDB1 in human
CRL4 and subsequent less efficient activation of DNA
damage response. The species-specificity of SIVagm Vpr
highlights adaptations that the virus has made to repli-
cate in its natural host species.
Methods
Expression plasmids
Amino-terminal hemagglutinin (HA)-tagged Vpr expres-
sion vectors pcHA-Vpr and pcVprL64P, HA-tagged UNG2
expression vector pcUNG2, myc-tagged SIV Vpr expres-
sion vectors pcVpr.agm and pcVpr.mac, and DCAF1/
VprBP expression system including pFSZ2-VprBP-FH,
pcRev, and pcTat plasmids have been previously described
[26,29]. SIVagm Vpr sequence in pcVpr.agm was derived
from the SIVagm.tan. pEGFP-C1 (Clontech) was used in
cell cycle analysis. To construct HA-tagged SIV Vpr ex-
pression vector, agm Vpr cDNA was amplified using
primers 5′-GGGGATATCATGGCAGAAGGAAGAGAT
TCCAGG-3′ and 5′-GGGCTCGAGCTATGCAAGTCC
TGGAGGAGGCTCTC-3′ from pcVpr.agm template. The
amplicon was digested with EcoR-V and Xho-I and cloned
into the pcHA-Vpr cleaved with Eco-RV and Xho-I. Ex-
pression vectors for VprR90K, VprR90D, and VprQ65R
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pcHA-Vpr. All vectors were confirmed by nucleotide
sequence analysis.Transfection and immunoblot analysis
Cells were cultured in DMEM supplemented with 10%
fetal bovine serum in a CO2 incubator at 37°C. For
transfections, the cells were seed and transfected the
next day using Lipofectamine 2000 (Invitrogen). Cell
lysates were prepared using buffer containing 0.5%
NP40, 10 mM Tris pH 8.0, 150 mM NaCl, and 2 mM
EDTA supplemented with protease inhibitor cocktail III
(Calbiochem). Lysates were cleared by centrifugation at
10,000 g for 10 min and the protein concentration was
determined by Bradford assay. Lysate (10 μg) was sepa-
rated by SDS-PAGE and transferred to an Invitrolon
PVDF membrane (Invitrogen). The membrane was
blocked with 5% non-fat milk in PBS with 0.05% Tween
20 (PBST) and probed with anti-HA MAb 16B12
(1:2,000) (Covance) for 1 h. The membrane was washed
with PBST and incubated with ImmunoPure biotin-
conjugated goat anti-mouse IgG (1:20,000) (Pierce) for
1 h. As a loading control, the membrane was stained
with anti-βtubulin MAb (1:1,000) (Sigma). The filters
were treated with Dylight 680-conjugated streptavidin
(Pierce) for 30 min and the proteins were detected and
quantified on an Odyssey Imager (Li COR). Primary
antibodies used for immunoblot analysis following im-
munoprecipitation were anti-myc MAb 9E10 (1:1,000)
(Covance), anti-DCAF1 antibody (1:5,000) (Shanhaige-
nomics), anti-Flag MAb M2 (1:1,000) (Sigma), anti-HA
3 F10 MAb (1:1000) (Roche), anti-DDB1 MAb (1:1,000)
(Zymed), anti-DDB1 antibody C-2 (1:500) (Santa Cruz),
anti-HA MAb 16B12, and anti-βtubulin MAb. In some
cases horseradish peroxidase (HRP)-conjugated secon-
dary antibodies (Invitrogen) were used and the signals
were detected using Luminata Forte Western HRP sub-
strate (Millipore) and LAS1000plus or ImageQuant LAS
4010 systems (Fuji Film and GE healthcare).siRNA knock-down
HeLa cells (1 × 105) were transfected with 100 pmol of
siRNA (Dharmacon) using Lipofectamine 2000. After
24 hours, the cells were transfected again with 1 μg
of pcHA-Vpr. After an additional 2 days, the cells
were lysed in IP lysis buffer (1% NP40, 50 mM Tris
pH 7.5, 150 mM NaCl, and 2 mM EDTA) supplemented
with protease inhibitor cocktail for immunoprecipi-
tation analysis. siRNA target sequences were: DCAF1,
5′-GGAGGGAAUUGUCGAGAAUUU-3′ (DCAF1-1)
and 5′-CGGAGUUGGAGGAGGACGAUU-3′ (DCAF1-2);
DDB1, 5′-CCUGUUGAUUGCCAAAAAC-3′. The siCON-
TOROL#3 (Dharmacon) was used as a control siRNA.Immunoprecipitation
293 T cells were seeded into 6-well plates (1 × 105/well)
and COS cells (1 × 106) were seeded into 10 cm dishes.
The cells were transfected at the following day and two
days posttransfection, the cells were lysed in 500 μl of IP
lysis buffer. The lysates were clarified by centrifugation
for 10 min at 10,000 g and precleared with protein-G
sepharose. A portion of the cleared lysate was retained
for immunoblot analysis and the remainder was incu-
bated with anti-HA MAb 16B12, anti-HA MAb 3 F10,
or anti-myc MAb 9E10 antibody bound to protein-G
sepharose for 2 h at 4°C. The samples were washed five
times with IP lysis buffer and resuspended in SDS-PAGE
sample buffer for immunoblot analysis.
Immunofluorescence
HeLa cells (1 × 105) were grown on a 35 mm glass bottom
dish (Matsunami) and transfected with 0.3 μg of pcHA-
Vpr expression plasmid. The transfected cells were fixed
with 2% paraformaldehyde in PBS for 15 min and perme-
abilized with 0.1% triton X-100 for 5 min at room
temperature. After blocking with 0.5% BSA in PBS for
30 min, the cells were incubated with anti-HA 3 F10 MAb
and anti-γH2AX (Abcam) antibodies for 16 hours at 4°C
followed by incubation with fluorescent-labeled secondary
antibodies. The cells were visualized with a BZ-8000
(KEYENCE) microscope. For colocalization analysis, the
transfected cells were permeabilized with 0.05% triton
X-100 and fixed in 2% paraformaldehyde. After blocking
with 0.5% BSA, the cells were incubated with anti-HA
3 F10 MAb and anti-DDB1 (Abcam) antibodies, and then
stained with fluorescent-labeled secondary antibodies. The
cells were imaged on a Zeiss LSM510 Meta laser scanning
confocal microscope (Zeiss). The secondary antibodies
used are Alexa Fluor 488-conjugated goat anti-rat IgG
(H+ L) and Alexa Fluor 594 goat anti-rabbit IgG (H + L)
(Invitrogen).
Cell cycle analysis
Cells were cotransfected with Vpr expression vectors and
pEGFP-C1 vectors. Two days posttransfection, the cells
were fixed in cold 75% ethanol, washed with PBS and
treated with 0.5 mg/ml RNase A for 30 min. The cells
were then stained with 0.05 μg/ml propidium iodide for
30 min and analyzed by flow cytometry in that the GFP+
cells were gated to focus on those that were successfully
transfected. The data were analyzed using FlowJo 8.5.2
software (Tree star).
Additional files
Additional file 1: Figure S1. Association of VprQ65R mutant with DCAF1
and DDB1. 293T cells were cotransfected with HA-Vpr or HA-VpQ65R and
Flag-DCAF1 expression vectors. Vpr was immunoprecipitated with anti-HA
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analysis with anti-Flag MAb, anti-DDB1 antibody, and anti-HA antibody.
Additional file 2: Figure S2. Cell cycle analysis of VprR90K and
VprR90D mutants. (A) 293T cells were transfected with HIV-1 Vpr or Vpr
mutant, Flag-DCAF1, and EGFP expression vectors. After staining with
propidium iodide, the cells were analyzed by flow cytometry. The G2:G1
ratio was calculated after gating for the GFP+ cells. The results are
representative of three independent experiments. (B) A portion of the
cells used in (A) was subjected to an immunoblot analysis to confirm
Vpr and Vpr mutants expression. The βtubulin was a loading control.
Additional file 3: Figure S3. Colocalization of VprR90K with DDB1.
HeLa cells were transfected with HA-Vpr or HA-VprR90K and Flag-DCAF1
expression vectors. The transfected cells were permeabilized, fixed, and
then incubated with anti-DDB1 and anti-HA antibodies followed by Alexa
Fluor 594-anti-rabbit IgG and Alexa Fluor 488-anti-rat IgG. The percentage
of Vpr foci colocalized with DDB1 among total Vpr foci was calculated.
More than 380 Vpr foci were evaluated for each sample and three
independent experiments were done. The data are the mean values
with standard deviations. P values were calculated by the Student’s t-test
with P < 0.05 considered significant.
Additional file 4: Figure S4. SIVagm HA-Vpr shows a defect in UNG2
degradation. 293T cells were transfected with increasing amounts
(0.05 μg, 0.1 μg, and 0.2 μg) of HA-Vpr or SIVagm HA-Vpr expression
vector together with a constant amount of HA-UNG2 and Flag-DCAF1
expression vectors. The cells were lysed, and then Vpr and UNG2 were
detected by immunoblot analysis with anti-HA antibody. The βtubulin
was a loading control.
Additional file 5: Figure S5. Phosphorylation of H2AX by Vpr. HeLa
cells (1 x 105) were transfected with 0.1 μg of HA-Vpr or SIVagm HA-Vpr
expression vector. Twenty-four hours after transfection, the cells were
lysed in sample buffer. Vpr and γH2AX in the cell lysate were detected by
immunoblot analysis. The βtubulin was a loading control.
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